🇺🇸 Hydrochlorothiazide 12.5mg in United States

60 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Angioedema — 19 reports (31.67%)
  2. Cough — 7 reports (11.67%)
  3. Acute Kidney Injury — 6 reports (10%)
  4. Dyspnoea — 6 reports (10%)
  5. Hyponatraemia — 5 reports (8.33%)
  6. Disease Progression — 4 reports (6.67%)
  7. Nausea — 4 reports (6.67%)
  8. Death — 3 reports (5%)
  9. Decreased Appetite — 3 reports (5%)
  10. Diarrhoea — 3 reports (5%)

Source database →

Hydrochlorothiazide 12.5mg in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Hydrochlorothiazide 12.5mg approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Hydrochlorothiazide 12.5mg in United States?

University of Kansas Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.